Junshi Biosciences Receives FDA Approval for PI3K-α Inhibitor RP903 in Breast Cancer Study
China’s Junshi Biosciences (HKG: 1877, SHA: 688180) announced that it has received approval from the...
Biotech
Abbisko Therapeutics Doses First Patient in ABSK061 Phase I Study for Solid Tumors
Shanghai-based biotech Abbisko Therapeutics Co., Ltd (HKG: 2256) announced the first patient dosing in a...
Harbour BioMed’s Partner NK Celltech Raises RMB 100M in Series A Financing
China-based Harbour BioMed (HKG: 2142) announced that its strategic partner NK Celltech, a company focusing...
Ascentage Pharma’s APG-5918 Receives FDA Approval for First-in-Human Study
Suzhou-based Ascentage Pharma (HKG: 6855) announced that it has received approval from the US Food...
Luzhu Bio Files for Hong Kong IPO After RMB 4.42 Billion Valuation
Beijing Luzhu Biotechnology Co., Ltd, a leading developer of human vaccines and therapeutic biologics, has...
Humanwell Healthcare Wins NMPA Approval for RFUS-144 in Pain Management
China-based Humanwell Healthcare (Group) Co., Ltd (SHA: 600079) announced receiving approval from the National Medical...
LaNova Medicines Secures Series B Funding to Advance Oncology Pipeline
China-based LaNova Medicines has successfully closed a Series B financing round, raising an undisclosed sum...
Beijing Luzhu Biotechnology Secures Series C Funding for Meningococcal Vaccine Development
China-based Beijing Luzhu Biotechnology Co., Ltd has reportedly secured an undisclosed amount in a Series...
Recbio’s R520A mRNA COVID-19 Vaccine Receives Clinical Approval in the Philippines
China-based Jiangsu Recbio Technology Co., Ltd has announced receiving clinical trial approval from the Food...
Sinovac Biotech’s CoronaVac Receives Conditional Registration from South African Regulator
China-based Sinovac Biotech Ltd (NASDAQ: SVA) has announced that the South African Health Products Regulatory...
Sino Biopharmaceutical’s TQ-B3101 Accepted by NMPA for ROS1+ NSCLC Treatment
China-based Sino Biopharmaceutical Ltd (HKG: 1177) has announced that the National Medical Products Administration (NMPA)...
Ascletis Pharma Presents ASC22 Phase IIb Results for Chronic Hepatitis B at ILC 2022
China-based Ascletis Pharma Inc. (HKG: 1672) presented the latest results of a Phase IIb clinical...
Westlake Therapeutics Secures RMB 100 Million in Series A+ Funding for Red Cell Therapy Pipeline
Hangzhou-based cell therapy firm Westlake Therapeutics, founded in 2019, has successfully raised over RMB 100...
Helixon Secures RMB 500 Million in Series A Round to Advance AI-Driven Drug Development
Beijing-based Helixon, an artificial intelligence (AI)-empowered pharmaceutical company, has reportedly secured RMB 500 million (USD...
BrightGene Bio-Medical Technology Gains NMPA Approval for Oseltamivir Dry Suspension
China-based BrightGene Bio-Medical Technology Co., Ltd (SHA: 688166) has announced receiving market approval from the...
CSPC’s JMT103 Accepted for Review in China, Targets RANKL-Related Deficiencies
The Center for Drug Evaluation (CDE) website indicates that a market filing by China-based CSPC...
Eureka Biotechnology Secures RMB 100 Million for Cell and Gene Therapy Solutions
Shenzhen-based Eureka Biotechnology, a company specializing in comprehensive solutions for the cell and gene therapy...
Therorna Secures Over RMB 280 Million in Series A Round to Accelerate circRNA Tech Development
China-based Therorna Inc., a biotech company specializing in cutting-edge circular RNA (circRNA) technology for next-generation...
Boehringer Ingelheim Venture Fund and Hong Kong Science Park Launch Co-Incubation Plan
Germany-based pharmaceutical giant Boehringer Ingelheim’s venture fund (BIVF) and China-based Hong Kong Science & Technology...
Shenzhen’s LWPOCT Secures RMB 100 Million in Series A Round for CDMO Expansion
Shenzhen-based medical devices and reagents manufacturer Shenzhen Living Water POCT Co., LTd (LWPOCT) has reportedly...